CompanyCABANasdaqPhiladelphia, PA

Cabaletta Bio

Cabaletta Bio develops targeted cell therapies for autoimmune diseases.

SEC EDGAR ClinicalTrials.gov cabalettabio.com

8-KSep 14Latest SEC filing, period to Sep 14

Aug 13Latest story

August 2026

Cabaletta reports Q2 2026 results, reaffirms mid-2027 myositis data and 2H27 BLA plan

Aug 13Quarterly updateCabaletta Bio